scholarly journals Perspective: Time to Resolve Confusion on Folate Amounts, Units, and Forms in Prenatal Supplements

2020 ◽  
Vol 11 (4) ◽  
pp. 753-759 ◽  
Author(s):  
Leila G Saldanha ◽  
Johanna T Dwyer ◽  
Carol J Haggans ◽  
James L Mills ◽  
Nancy Potischman

ABSTRACT Folate-containing prenatal supplements are commonly consumed in the United States, but inconsistencies in units of measure and chemical forms pose challenges for providing authoritative advice on recommended amounts. New regulations require folate to be declared as micrograms of dietary folate equivalents (DFE) on product labels, whereas intake recommendations for reducing the risk of neural tube defects (NTDs) and the Tolerable Upper Intake Level are expressed as micrograms of folic acid. Today, >25% of prenatal supplements contain folate as synthetic salts of L-5-methyltetrahydrofolate (L-5-MTHF), but recommendations do not include this form of the vitamin. Harmonizing units of measure and addressing newer forms of folate salts in intake recommendations and in the prevention of NTDs would resolve the confusion.

1991 ◽  
Vol 11 (8) ◽  
pp. 641-648 ◽  
Author(s):  
Joe Leigh Simpson ◽  
James L. Mills ◽  
George G. Rhoads ◽  
George C. Cunningham ◽  
Howard J. Hoffman ◽  
...  

2008 ◽  
Vol 169 (1) ◽  
pp. 9-17 ◽  
Author(s):  
B. S. Mosley ◽  
M. A. Cleves ◽  
A. M. Siega-Riz ◽  
G. M. Shaw ◽  
M. A. Canfield ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Richard H. Finnell ◽  
Carlo Donato Caiaffa ◽  
Sung-Eun Kim ◽  
Yunping Lei ◽  
John Steele ◽  
...  

Human structural congenital malformations are the leading cause of infant mortality in the United States. Estimates from the United States Center for Disease Control and Prevention (CDC) determine that close to 3% of all United States newborns present with birth defects; the worldwide estimate approaches 6% of infants presenting with congenital anomalies. The scientific community has recognized for decades that the majority of birth defects have undetermined etiologies, although we propose that environmental agents interacting with inherited susceptibility genes are the major contributing factors. Neural tube defects (NTDs) are among the most prevalent human birth defects and as such, these malformations will be the primary focus of this review. NTDs result from failures in embryonic central nervous system development and are classified by their anatomical locations. Defects in the posterior portion of the neural tube are referred to as meningomyeloceles (spina bifida), while the more anterior defects are differentiated as anencephaly, encephalocele, or iniencephaly. Craniorachischisis involves a failure of the neural folds to elevate and thus disrupt the entire length of the neural tube. Worldwide NTDs have a prevalence of approximately 18.6 per 10,000 live births. It is widely believed that genetic factors are responsible for some 70% of NTDs, while the intrauterine environment tips the balance toward neurulation failure in at risk individuals. Despite aggressive educational campaigns to inform the public about folic acid supplementation and the benefits of providing mandatory folic acid food fortification in the United States, NTDs still affect up to 2,300 United States births annually and some 166,000 spina bifida patients currently live in the United States, more than half of whom are now adults. Within the context of this review, we will consider the role of maternal nutritional status (deficiency states involving B vitamins and one carbon analytes) and the potential modifiers of NTD risk beyond folic acid. There are several well-established human teratogens that contribute to the population burden of NTDs, including: industrial waste and pollutants [e.g., arsenic, pesticides, and polycyclic aromatic hydrocarbons (PAHs)], pharmaceuticals (e.g., anti-epileptic medications), and maternal hyperthermia during the first trimester. Animal models for these teratogens are described with attention focused on valproic acid (VPA; Depakote). Genetic interrogation of model systems involving VPA will be used as a model approach to discerning susceptibility factors that define the gene-environment interactions contributing to the etiology of NTDs.


2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Leila Saldanha ◽  
Johanna Dwyer ◽  
Nancy Potischman ◽  
Karen Andrews

Abstract Objectives Most prenatal supplements available in the US contain synthetic folic acid. We compared the labeled amounts of folic acid in prenatal supplements with: 1) the Recommended Dietary Allowance (RDA) of 360 mcg and Tolerable Upper Intake Level (UL) of 1000 mcg for pregnant women established by National Academies of Science, Engineering and Medicine's Food and Nutrition Board (FNB) and expressed as synthetic folic acid from supplements and fortified foods; 2) current population-based Daily Values (DV) used for labeling dietary supplements and established by the US Food and Drug Administration (FDA); 3) FDA criteria for making a neural tube defects health claim on prenatal supplement labels; and 4) 2009/2016 recommendations for the prevention of neural tube defects by the US Preventive Services Task Force (USPSTF). In 2016, the FDA revised its DV to 600 mcg DFE folate (360 mcg folic acid) to reflect amounts consistent with the RDAs. This new DV is lower than the pre-2016 DV of 800 mcg from food and supplement sources and the 800 mcg level to make a health claim. Methods We reviewed the synthetic folic acid content as declared on prenatal supplement labels sold with and without a prescription, using data in the Dietary Supplements Label Database (DSLD) (website: https://dsld.nlm.nih.gov/dsld/) and DailyMed (website: https://dailymed.nlm.nih.gov/dailymed/index.cfm). Results The many recommendations for folate versus folic acid are often unclear (e.g., Dietary Folate Equivalents vs. mcg folic acid). Amounts ≥ 800 mcg folic acid per serving, the prior DV, were present on 99% of 79 prescription and 91% of 121 nonprescription labels reviewed. 94% of the prescription and 16% of nonprescription prenatal supplements were labeled at 1000 mcg per serving, and none (0%) of the prescription and 74% of the nonprescription were labeled at 800 mcg. These labeled amounts (from supplements alone) were higher than the USPSTF recommended daily intake of 400 to 800 mcg and the current DV and RDA values. Conclusions The DV, UL, the criterion for making a health claim on prenatal supplement labels, the USPSTF recommendations, and the units used for expressing folate and folic acid recommendations need to be harmonized and clarified. Funding Sources Office of Dietary Supplements, NIH.


2008 ◽  
Vol 15 (4) ◽  
pp. A27-A27
Author(s):  
J Petrini ◽  
Rb Russell ◽  
K Damus ◽  
C Alter ◽  
D Mattison

Sign in / Sign up

Export Citation Format

Share Document